Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ImageneBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ImageneBio's regulatory disclosures and financial reporting.
ImageneBio, Inc. filed an initial Form 3 identifying Yanina Grant-Huerta as its Chief Financial Officer and reporting person. The data shows no insider transactions, holdings entries, or derivative positions, and references an Exhibit 24 Power of Attorney authorizing filings on her behalf.
ImageneBio, Inc. Chief Executive Officer Kristin Yarema reported RSU-related changes in ownership. On July 25, 2026, 38,376 restricted stock units were exercised into 38,376 shares of common stock at $0.0000 per share. An additional 115,129 unvested RSUs from a July 28, 2025 grant were reclassified and now appear as common stock holdings; no purchase or sale transactions are reported.
ImageneBio, Inc. filed a prospectus supplement covering the proposed resale, from time to time, of 2,508,337 shares of common stock by selling stockholders under an existing Form S-1. The common stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sale price was $5.97 per share on July 22, 2026.
The company also appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026. Her employment terms include a $450,000 annual base salary, eligibility for an annual discretionary bonus targeted at 40% of base salary, an initial option to purchase 95,000 shares, and 65,000 restricted stock units, each vesting over four years. She will participate as a C-suite officer in the company’s Severance and Change in Control Plan, which can provide up to 12 months of salary, a 100% target bonus payout, continued health benefits for up to 12 months, and full equity acceleration upon a qualifying covered termination during a change in control period.
Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time role to a consulting position, continuing to advise on clinical development and strategy.
ImageneBio, Inc. appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026, succeeding CEO Kristin Yarema, Ph.D., in her interim finance role. Grant-Huerta previously held senior finance positions at Atara Biotherapeutics and Amgen.
Under an employment agreement, she receives an annual base salary of $450,000, is eligible for a discretionary annual bonus equal to 40% of base salary, and is granted 65,000 restricted stock units and a stock option for 95,000 shares, each vesting over four years, subject to continued employment. She will participate in ImageneBio’s Severance and Change in Control Plan, which provides 12 months of salary and up to 12 months of health benefits, plus an additional lump sum equal to 100% of target bonus and full equity acceleration upon certain covered terminations during a change in control period. Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time executive role to a consulting clinical development and strategic advisory position.
ImageneBio, Inc. Principal Accounting Officer Robert B. Lally reported selling a total of 3,196 shares of Common Stock in open-market transactions on July 16–17, 2026. Sales included 1,671 shares at a weighted average price of $5.50 (range $5.45–$5.635) and 1,525 shares at $5.34 (range $5.32–$5.3527).
ImageneBio, Inc. filed a prospectus supplement to its Form S-1 registering the resale or other disposition of 2,508,337 shares of Common Stock. The supplement incorporates portions of a Form 8-K noting that Senior VP of Finance and Operations Robert Lally gave notice of resignation, effective July 22, 2026. The supplement states the last reported sales price was $6.02 per share on June 26, 2026 and that the selling stockholders, identified in the prospectus, propose to offer those shares from time to time.
Imagenebio, Inc. reported that Robert Lally, its Senior Vice President of Finance and Operations and principal accounting officer, has resigned. He notified the company on June 22, 2026, and his resignation will be effective July 22, 2026. The company stated that his departure is not due to any disagreement with Imagenebio. Management plans to conduct a search for his replacement.
ImageneBio, Inc. director Jonathan Jian Wang received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036.
The options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control under the 2025 Equity Incentive Plan.
ImageneBio, Inc. director Otello Stampacchia received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036. All 15,600 options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. Following this grant, Stampacchia holds 15,600 stock options directly.
ImageneBio, Inc. director Joseph P. Slattery reported receiving a stock option grant as equity compensation. The award covers 15,600 shares of common stock at an exercise price of $5.45 per share, expiring on June 16, 2036.
According to the terms, the option vests in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. After this grant, Slattery holds options for 15,600 shares directly.